方之光 ◎记者 王墨璞嘉 在他看来，传统药品包装往往呆板单调，消费者难以一眼看清产品用途，更谈不上体验感，而小方制药 要做的，就是让药品既要有硬核的疗效，也要有贴合现代生活的设计与体验。 作为沪市主板外用药龙头，小方制药产品涵盖消化类、皮肤类、五官类等领域共60余个药品，其中开塞 露、炉甘石洗剂、氧化锌软膏等核心产品市占率稳居全国前三，信龙品牌开塞露十年累计销量达数十亿 支。 但方之光并未止步于既有成绩，而是从设计入手全面焕新产品。摒弃传统的白色长条包装，小方制药的 新品融入克莱因蓝、毕加索画作等潮流元素，开塞露也被打造成兼具设计感与实用性的产品，推出了分 男女款的个性化设计。 在产品体验打磨上，方之光同样事无巨细。针对用户的多元化使用偏好：为甘油醇溶液特别定制了精密 喷头，用户使用时无须手动涂抹，就能缓解皮肤干燥、皲裂等问题；开塞露瓶子采用专利设计，口径更 细，瓶体从椭圆形升级为扁球形，既提升了使用安全性，又提高了药液挤压率。 "我们做的是家庭常备药，就要把每个细节都想到消费者心坎里。"方之光表示。他的执着，让小方制药 的产品形成了"疗效实在、品质稳定、设计贴心"的独特标签。 深耕新零售 构筑全渠道网络 近 ...

Core Insights - The article highlights the success of Xiaofang Pharmaceutical in the family-oriented external medicine sector, emphasizing its innovative product iterations and marketing strategies to enhance user retention and drive sales growth [1][2][3] Group 1: Product Development and Innovation - Xiaofang Pharmaceutical has focused on continuous product iteration and marketing innovation, launching the W-type Kaisi Lu with a unique packaging design to improve medication effectiveness [2] - The company has developed multiple new sub-brands and products, including Xinlong Hongtun and Long Yidian, targeting specific health needs such as oral ulcers and throat inflammation [2][3] - The company is also working on a new traditional Chinese medicine for hair loss, in collaboration with Shanghai Skin Disease Hospital, aiming to enter a promising market [3] Group 2: E-commerce and New Retail Strategy - Xiaofang Pharmaceutical has embraced the new retail trend, establishing partnerships with major e-commerce platforms like Alibaba Health and JD Health to enhance product visibility and sales [3][4] - The company utilizes Kaisi Lu as a "traffic entry point" for online sales, achieving over 300 million annual exposures on a single platform, and employs cross-selling strategies to promote related products [4][5] - The company is implementing a digital inventory monitoring system to prevent stockouts and ensure timely product availability, enhancing customer satisfaction [5] Group 3: Supply Chain and Operational Efficiency - Xiaofang Pharmaceutical is advancing towards a fully digital supply chain, aiming for real-time responses and efficient inventory management to meet consumer demands [5][6] - The company is constructing a smart factory for external medicine production, focusing on automation and efficiency to support growing production needs [6][7] - The company plans to implement a "dual-wheel drive" strategy, focusing on both technological innovation in drug development and enhancing market access through digital tools [7]

Core Viewpoint - The incidence of chronic constipation is rising in China, with a prevalence rate between 4% and 10%, particularly higher in women and increasing with age [1] Group 1: Patient Demographics and Impact - The number of chronic constipation patients at Tianjin People's Hospital has significantly increased due to changes in diet, lifestyle, and psychological factors [1] - Chronic constipation severely affects the quality of life, leading many patients to self-medicate or rely on long-term prescriptions, which can pose safety risks and delay diagnosis of underlying conditions [1] Group 2: Types of Laxatives - **Bulk-forming Laxatives**: Examples include polycarbophil and wheat cellulose; they are safe for long-term use and suitable for mild constipation, especially in pregnant women and the elderly [2] - **Osmotic Laxatives**: Examples include polyethylene glycol 4000 and lactulose; they soften stool and stimulate bowel movement, suitable for mild to moderate constipation [2] - **Stimulant Laxatives**: Examples include bisacodyl and senna; they act quickly but can lead to dependency and electrolyte imbalances if used long-term [3] - **Lubricant Laxatives**: Examples include glycerin suppositories and liquid paraffin; they provide rapid relief for short-term constipation [3] - **Prokinetic Agents**: Examples include mosapride and itopride; they enhance gut motility and are used in conjunction with other laxatives [3] - **Secretagogues**: Examples include linaclotide; they are prescribed for chronic constipation unresponsive to standard treatments [3] - **Probiotics**: Examples include various strains of Bacillus and Bifidobacterium; they help restore gut flora and improve bowel function, recommended for long-term use [3]

Industry Overview - The constipation issue is becoming increasingly common due to aging population, fast-paced lifestyle, and changing dietary habits, driving the consumption of laxative products like glycerin enemas [1][10] - The Chinese glycerin enema market is projected to reach a sales revenue of 1.157 billion yuan in 2024, representing a year-on-year growth of 9.36% [1][10] - Glycerin enemas are classified into glycerin-based and mannitol/magnesium sulfate formulations, acting directly on the rectum to stimulate bowel movements [4] Industry Development History - The industry has evolved through three main stages: initial growth in the 1980s-90s, rapid development in the early 2000s to 2010s, and innovation and diversification from the 2020s onwards [4] - The early stage saw limited product variety and reliance on chemical ingredients, while the later stages shifted towards plant extracts and herbal components to reduce side effects [4] - Recent trends include the introduction of high-end product lines and stricter regulatory requirements, enhancing product safety and efficacy [4] Industry Supply Chain - The upstream of the glycerin enema industry includes raw materials like glycerin and production equipment [6] - The midstream involves the manufacturing of glycerin enemas, while the downstream encompasses sales channels such as medical institutions, retail pharmacies, and e-commerce platforms [6] Current Industry Status - The market is experiencing a shift towards natural and effective products, with innovations in dosage forms like gel and granule types to meet consumer demands for convenience and lower residue [10] - Companies are increasingly incorporating plant extracts and herbal ingredients to enhance product appeal and reduce irritation [10] Key Companies' Performance - Shanghai Xiaofang Pharmaceutical Co., Ltd. leads the market with a 38.3% share in 2024, leveraging its "Xinlong" brand and innovative W-type enema design to enhance user experience [12][14] - Beijing Fuyuan Pharmaceutical Co., Ltd. focuses on cost-effective strategies, achieving a production volume of 640 million units in 2024, with a year-on-year increase of 12% [12][16] - The competitive landscape is characterized by a few dominant players and numerous smaller firms employing differentiation strategies to capture niche markets [12] Industry Development Trends 1. **Growing Market Demand**: The demand for glycerin enemas is expected to continue rising, driven by an aging population and increasing health awareness, particularly among the elderly and younger demographics facing lifestyle-related constipation [18] 2. **Accelerated Competitive Differentiation**: The industry is witnessing a shift towards higher concentration, with leading companies solidifying their market positions through brand strength and innovative products [19] 3. **Technological and Product Innovation**: The industry is moving towards diversification and high-end formulations, with a focus on optimizing dosage forms and incorporating beneficial ingredients like prebiotics and probiotics [20]

Core Viewpoint - The company Xiaofang Pharmaceutical (603207) is officially entering the field of traditional Chinese medicine compound preparation new drug development by collaborating with Shanghai Dermatology Hospital to develop a new product for hair loss treatment [2][3]. Group 1: Collaboration and Product Development - Xiaofang Pharmaceutical has signed a cooperation agreement with Shanghai Dermatology Hospital to jointly develop a new drug, Compound Cèbǎi Tincture, aimed at treating various types of hair loss [2]. - The collaboration aims to obtain the new drug (Class 1.1) market approval from the National Medical Products Administration, involving preclinical research and clinical trials [2][3]. - The company will pay a total of 20 million yuan for technology transfer and support, with additional sales commissions after the product is launched [2]. Group 2: Market Potential and Strategic Focus - According to the National Health Commission, the number of people suffering from hair loss in China has exceeded 250 million, with a noticeable increase in younger demographics aged 20-40 due to economic and lifestyle pressures [2]. - The Compound Cèbǎi Tincture has been well-received by patients and shows promising development prospects, potentially becoming the first traditional Chinese medicine preparation for hair loss in China [3]. - Xiaofang Pharmaceutical has a strong focus on over-the-counter external medications and aims to expand its product pipeline while optimizing research and development structures to meet family health needs [3].

Core Viewpoint - The company, Shanghai Xiaofang Pharmaceutical Co., Ltd., focuses on the development, production, and sales of external-use medications, with a strong emphasis on non-prescription drugs and a commitment to enhancing market presence through brand innovation and strategic marketing efforts [5][10]. Company Overview - The company operates in the pharmaceutical manufacturing industry, primarily concentrating on the research, production, and sales of external-use medications [5]. - The company aims to provide a wide range of high-quality external-use medications that are easy to store and use, positioning itself as a household name for common ailments [10]. Market Trends - The aging population and increasing health awareness are driving demand for external-use medications, as older adults are more susceptible to skin and digestive diseases [6][7]. - The rise of e-commerce and online sales channels has improved the accessibility of external-use medications, significantly broadening the market reach [8][9]. - Government policies supporting the use and research of external-use medications are enhancing market conditions, making these products more affordable and accessible to patients [9]. Financial Performance - In 2024, the company achieved a revenue of 474.58 million yuan, a year-on-year increase of 0.57%, and a net profit attributable to shareholders of 205.27 million yuan, up 0.81% from the previous year [18]. - The total assets of the company reached 1.40 billion yuan, reflecting a growth of 96.79% compared to the beginning of the year, while the equity attributable to shareholders increased by 112.82% to 1.23 billion yuan [18]. Profit Distribution Plan - The company plans to distribute a cash dividend of 15.00 yuan per 10 shares (including tax), totaling approximately 240.84 million yuan, which represents 117.33% of the net profit attributable to shareholders for 2024 [3][4].

上海小方制药股份有限公司 Shanghai Xiao Fang Pharmaceutical Co.,Ltd. （发行人地址：上海市奉贤区洪朱路 777 号） 首次公开发行股票并在主板上市招股说明书 保荐人（主承销商） （注册稿） （地址：深圳市罗湖区红岭中路 1012 号国信证券大厦十六至二十六层） 上海小方制药股份有限公司 招股说明书（注册稿） 重要声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 上海小方制药股份有限公司 招股说明书（注册稿） 本次发行概况 本公司的发行申请尚需经交易所和中国证监会履行相应程序。本招股说明书 不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以正 ...

上海小方制药股 Shanghai Xiao Fang Pharr td. (发行人地址:上海市奉贤区洪朱路 777 号) 点小方制药 首次公开发行股票并在主板上市招股说明书 (上会稿) 保荐人(主承销商) 国信证券股份有限公司 GUOSEN SECURITIES CO.,LTD. (地址:深圳市罗湖区红岭中路1012 号国信证券大厦十六至二十六层) 上海小方制药股份有限公司 招股说明书（上会稿） 重要声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 上海小方制药股份有限公司 招股说明书（上会稿） 本次发行概况 本公司的发行申请尚需经交易所和中国证监会履行相应程序。本招股说明书 不具有据以发行 ...

上海小方制药股份有限公司 Shanghai Xiao Fang Pharmaceutical Co.,Ltd. （发行人地址：上海市奉贤区洪朱路 777 号） 首次公开发行股票并在主板上市招股说明书 （申报稿） 保荐人（主承销商） （地址：深圳市罗湖区红岭中路 1012 号国信证券大厦十六至二十六层） 上海小方制药股份有限公司 招股说明书（申报稿） 重要声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 上海小方制药股份有限公司 招股说明书（申报稿） 本次发行概况 本公司的发行申请尚需经交易所和中国证监会履行相应程序。本招股说明书 不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以正 ...